The GLP-1 drugs are revolutionizing the way people eat and spend their money, according to a recent survey. The survey reveals that approximately three million Canadian adults are currently taking GLP-1 drugs like Ozempic or Mounjaro, and many more are interested in doing so. However, cost is a significant barrier for many. The poll conducted by Leger Healthcare found that over half of the people surveyed who are taking the medications reported decreased appetite and 40% said they have fewer food cravings. This is reshaping how GLP-1 users are spending their money, with about 30% going to restaurants or getting takeout food less often. In addition to not going to restaurants as often, about 35% of people taking the medications said they order smaller portions than they used to, choose "lighter or healthier options," or don’t finish their whole meal. Thirty-six per cent said they have decreased their alcohol consumption. GLP-1 use is also changing what people buy outside of the grocery store, the survey said, with increased spending on clothes, personal care products, beauty services and fitness. The survey findings also estimate that about two million Canadian adults are not taking the medications but would like to. Although lack of insurance coverage and cost were barriers for about half of respondents interested in taking GLP-1s, another 36% said they would take the medication if the risk of side-effects was lower. Some people experience gastrointestinal side-effects including nausea, vomiting, constipation and diarrhea. More severe complications can include gall bladder inflammation and pancreatitis, but most side-effects are minor, doctors say. Fifty-eight per cent of people taking or considering taking GLP-1 drugs said weight loss was their main driver, while 42 per cent said diabetes was their primary reason. Twenty-two per cent said they wanted to take a GLP-1 for their heart health. Men were more likely to cite this reason than women. The survey found a quarter of the respondents taking GLP-1 medications were paying for the drugs – which can cost hundreds of dollars a month – completely out of pocket. The medication was fully covered by either private or public insurance plans for 28 per cent of them. Almost half said they had partial insurance coverage. Leger Healthcare conducted the online survey with 1,536 Canadians aged 18 and over from Feb. 6 to 9, 2026. Eight per cent of the respondents said they were taking a prescription GLP-1 medication. Using 2025 adult population statistics, Leger Healthcare extrapolated that would equal about three million Canadian adults. Similarly, six per cent of respondents said they were interested in taking a GLP-1 but weren’t. The researchers extrapolated that would translate to more than two million Canadian adults. The polling industry’s professional body, the Canadian Research Insights Council, says online surveys cannot be assigned a margin of error because they do not randomly sample the population. However, a probability sample of comparable size would yield a margin of error of ±2.5 per cent (19 times out of 20), according to Leger Healthcare.
